Under the research collaboration, Tempus will provide molecular sequencing and analysis services to patients enrolled in a Taussig Cancer Institute-run precision oncology clinical study. The study’s investigators will use this information to attempt to identify targeted therapies or clinical trials for patients with metastatic or incurable cancers.
“Incorporating advanced genomic data may enhance our ability to analyze vast amounts of clinical and molecular data, as we seek to improve the treatment options for our patients,” said Brian J. Bolwell, MD, chairman of the Taussig Cancer Institute.
More articles on data analytics & precision medicine:
Brigham Health deploys Redox systemwide to consolidate patient data
6 thoughts on healthcare data mining from attorneys James Nelson & Thora Johnson
IBM health officer heads to Cota as CMO
